CDT (Conduit Pharmaceuticals) Sale Of Property, Plant, Equipment : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Conduit Pharmaceuticals Sale Of Property, Plant, Equipment?

Conduit Pharmaceuticals's sale of property, plant, equipment for the three months ended in Sep. 2024 was $0.00 Mil. It means Conduit Pharmaceuticals gained $0.00 Mil from selling property, plant, and equipment. Conduit Pharmaceuticals's sale of property, plant, equipment for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Jun. 2024 ), Conduit Pharmaceuticals gained the same money from selling property, plant, and equipment in Sep. 2024 ($0.00 Mil).

Conduit Pharmaceuticals Sale Of Property, Plant, Equipment Historical Data

The historical data trend for Conduit Pharmaceuticals's Sale Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Sale Of Property, Plant, Equipment Chart

Conduit Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Sale Of Property, Plant, Equipment

Conduit Pharmaceuticals Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Sale Of Property, Plant, Equipment	Get a 7-Day Free Trial						-	-	-	-	-

Conduit Pharmaceuticals Sale Of Property, Plant, Equipment Calculation

The amount earned to sell PPE.

Sale Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Conduit Pharmaceuticals Sale Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Sale Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Conduit Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (NAS:CDT) » Definitions » Sale Of Property, Plant, Equipment

Comparable Companies

Traded in Other Exchanges

ZK7:Germany

Address

4995 Murphy Canyon Road, Suite 300, San Diega, CA, USA, 92123

Website

https://www.conduitpharma.com

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Executives

Andrew Regan	director, 10 percent owner	LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133
Intelmed Llc	other: See Responses	11421 GOLDEN EAGLE COURT, NAPLES FL 34120
Jennifer Isacoff Mcnealey	director	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121
David Tapolczay	director, officer: Chief Executive Officer	32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Algo Holdings, Inc.	10 percent owner, other: See Responses	100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309
Corvus Capital Ltd.	10 percent owner, other: See Responses	WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107
Freda C Lewis-hall	director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
James Bligh	director	38 OXBERRY AVENUE, LONDON X0 SW6 5SS
Shaolin Capital Management Llc	10 percent owner	230 NW 24TH STREET, SUITE 603, MIAMI FL 33127
Richard Edward Feinberg	director	2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103
Murphy Canyon Acquisition Sponsor, Llc	10 percent owner	4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123
Chele Chiavacci Farley	director	4 RIDGE ROAD, TUXEDO PARK NY 10987
Bentzen Edwin H Iv	officer: Chief Accounting Officer	2513 BIRCH HOLLOW ST, HENDERSON NV 89044
Jack Kendrick Heilbron	director, officer: CEO, President, and Chairman	16433 BRONCO LANE, POWAY CA 92064